Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Wed, 02nd Oct 2019 11:59

(Alliance News) - Motif Bio PLC on Wednesday said it intends to raise GBP600,000 through a 142.9 million share placing priced at 0.42 pence per share in order to fund its restructuring programme.

Shares in Motif were up 13% at 0.68p in London in late morning trade.

Motif will be holding a general meeting where shareholders will vote on the winding down or disposal of Motif's US subsidiary, Motif Biosciences Inc, and on the issue of placing shares at less than their 1 pence per share nominal value.

The placing is subject to the passing of these resolutions, as well as resolutions to make changes to Motif's articles of association and renew the firm's authority so that it can grant a warrant over 20% of it share capital to Hercules Capital Inc.

In 2017, Motif agreed up to USD20 million of debt financing from Hercules in two tranches. Motif drew down the first USD15.0 million tranche but did not meet the milestones for the second tranche of USD5.0 million. This was amended in February 2019 and in March the firm made USD7.5 million of early repayments.

A new deal has now been agreed, and was announced in its half-year report on Monday. Should shareholders approve a new agreement between the two companies, it has been decided that Hercules will relinquish its loan guarantee from Motif and relieve future obligations. Motif Biosciences Inc will then wind down operations and hire an advisor so it can sell its assets, including antibiotic iclaprim, ideally selling the drug to a firm who would commercialise it.

Hercules will then be given a perfected security interest in all Motif Biosciences Inc's intellectual property as well as a warrant for another 20% of Motif's shares an a 5 pence per share exercise price.

As a result, Motif would be "relieved of the liability and guarantee for the Hercules loan of approximately USD6.9 million".

Following this arrangement, Motif will become a cash shell under AIM rule 15, giving it six months to make a reverse acquisition or have its shares cancelled.

Should the capital raise not go ahead and the deal fail to gain shareholder support, then Motif will be forced to cease its operations and its shares would be suspended.

SP Angel Corporate Finance LLP is acting as bookrunner on the conditional placing.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
3 Jul 2018 10:47

Motif Bio Director Robert Bertoldi To Resign From Role July 16

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Motif Bio PLC said Tuesday that Director Robert Bertoldi will resign from the board with effect on July 16.Chief Executive

Read more
23 May 2018 14:39

Amphion Sells 8.9 Million Shares In Motif Bio To Repay Loan Facility (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC said on Wednesday it sold 8.9 million shares in partner company Motif Bio PLC to partially repay a loan facility, as well as to fund ongoing &

Read more
17 May 2018 14:56

UPDATE: Motif Bio Completes GBP10 Million Fundraise Through Placing (ALLISS)

LONDON (Alliance News) - Biopharmaceutical firm Motif Bio PLC said it has successfully raised GBP10 million via an accelerated bookbuild exercise on Thursday.The company placed 32.3 million

Read more
17 May 2018 12:20

Motif Bio To Raise GBP10 Million Via Accelerated Share Bookbuild (ALLISS)

LONDON (Alliance News) - Motif Bio PLC said it plans to raise GBP10 million via an accelerated bookbuild exercise, which will launch on Thursday.The funds raised will be used by the company

Read more
19 Apr 2018 13:59

Motif Bio's Iclaprim Delivers Continued Good Test Results

LONDON (Alliance News) - Motif Bio PLC on Thursday said iclaprim delivered further positive results as part of its REVIVE-2 phase three trial.Motif Bio previously had said iclaprim showed a

Read more
20 Mar 2018 11:08

Motif Bio Delays Iclaprim New Drug Application, Shares Fall

LONDON (Alliance News) - Motif Bio PLC's shares fell on Tuesday as the biopharmaceutical company said it has pushed back the date for its new drug application submission a

Read more
7 Mar 2018 13:24

Motif Bio Issues 178,571 Shares Following Warrants Exercise (ALLISS)

LONDON (Alliance News) - Motif Bio PLC said Wednesday it has raised GBP57,499 through the issue of 178,571 shares at a price of 32.2 pence per of

Read more
31 Oct 2016 10:58

Motif Bio may need to raise cash as antibiotic trial accelerates

(ShareCast News) - As it prepares to list on the Nasdaq, AIM-listed antibiotics developer Motif Bio said it was likely to need extra funding as enrolments for its latest clinical trial were going faster than expected. Patient enrolment in Motif's Revive 1 phase-three trial has exceeded projections a

Read more
9 Aug 2016 09:43

WINNERS & LOSERS SUMMARY: Worldpay Bid Up After Strong First Half

Read more
13 Jul 2016 09:43

WINNERS & LOSERS SUMMARY: Poundland Jumps On Steinhoff Takeover Deal

Read more
13 Jul 2016 08:13

Motif Bio Shares Rise As It Files To List On NASDAQ Market (ALLIPO)

Read more
23 Jun 2016 09:01

Amphion Reports Huge Net Asset Value Rise Thanks To Motif Bio

Read more
28 Apr 2016 09:01

Amphion Innovations To Draw Debt To Repay Existing Borrowings

Read more
20 Apr 2016 07:31

Motif Bio Loss Widens In 2015 As It Continues Iclaprim Progression

Read more
14 Apr 2016 07:52

Motif Bio Appoints New Chief Financial Officer, Clinical Operations VP

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.